Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation, and methods of use thereof
First Claim
1. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to a hybridization probe, wherein the probe is a member of the group consisting of SEQ ID NO 7, SEQ ID NO 16, and SEQ ID NO 34;
- or wherein the probe is a member of the group consisting of complements of SEQ ID NO 7, SEQ ID NO 16, and SEQ ID NO 34.
1 Assignment
0 Petitions
Accused Products
Abstract
The application is related to the field of nucleic acids with identified utility, and more particularly, to genes, related nucleic acids, their complements, polypeptides, and methods of using the same for blood vessel, cartilage, and bone formation, as well as inhibition thereof. The application describes discoveries made using the zebrafish embryo technique, as well as other techniques that are described herein. The discoveries include genes, related nucleic acids, and their complements, as well as sequences, polypeptides, other molecules, and methods for using them, e.g., TDE1, PTV, MOESIN, and HKE4. Also described are polypeptide products, inhibition of expression, administration of materials and products, screening procedures, and techniques for making drugs. Moreover, uses of these discoveries in appropriate contexts are set forth.
36 Citations
84 Claims
-
1. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to a hybridization probe, wherein the probe is a member of the group consisting of SEQ ID NO 7, SEQ ID NO 16, and SEQ ID NO 34;
- or wherein the probe is a member of the group consisting of complements of SEQ ID NO 7, SEQ ID NO 16, and SEQ ID NO 34.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- 12. An isolated nucleic acid comprising a sequence that is at least 90% identical to a member of the group consisting of SEQ ID NO 7, SEQ ID NO 16, SEQ ID NO 34, and complements thereof.
-
20. A composition, the composition comprising:
an isolated polypeptide comprising an amino acid sequence that is at least 8 residues in length and is at least 90% identical to a member of the group consisting of SEQ ID NO 3, SEQ ID NO 6, SEQ ID NO 9, SEQ ID NO 12, SEQ ID NO 15, SEQ ID NO 18, SEQ ID NO 30, SEQ ID NO 33, and SEQ ID NO 36. - View Dependent Claims (21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 34, 35, 36, 37, 38, 39)
- 31. An antisense polynucleic acid comprising a sequence, wherein the antisense polynucleic acid suppresses the expression of a polypeptide encoded by a polynucleic acid sequence for the polypeptide chosen from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 22, SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 26, SEQ ID NO 28, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 34, and SEQ ID NO 35.
-
40. A vector, the vector comprising:
-
a first nucleic acid sequence that hybridizes under stringent conditions to a second nucleic acid sequence, wherein the second sequence is a member of the group consisting of SEQ ID NO 1, SEQ ID NO 4, SEQ ID NO 7, SEQ ID NO 10, SEQ ID NO 13, SEQ ID NO 16, SEQ ID NO 19, SEQ ID NO 22, SEQ ID NO 25, SEQ ID NO 28, SEQ ID NO 31, SEQ ID NO 34, or wherein the second sequence is a member of the group consisting of complements of SEQ ID NO 1, SEQ ID NO 4, SEQ ID NO 7, SEQ ID NO 10, SEQ ID NO 13, SEQ ID NO 16, SEQ ID NO 19, SEQ ID NO 22, SEQ ID NO 25, SEQ ID NO 28, SEQ ID NO 31, SEQ ID NO 34;
wherein the first nucleic acid sequence is operably linked to an expression control sequence that directs production of a transcript from the first nucleic acid sequence. - View Dependent Claims (41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)
-
- 55. A method of using a composition, the method comprising administering a composition to an animal, the composition comprising a polypeptide having an amino acid sequence that is at least 90% identical to a member of the group consisting of SEQ ID NO 3, SEQ ID NO 6, SEQ ID NO 9, SEQ ID NO 12, SEQ ID NO 15, SEQ ID NO 18, SEQ ID NO 30, SEQ ID NO 33, SEQ ID NO 36.
-
70. A method, the method comprising:
administering a vector to an animal, the vector comprising;
a first nucleic acid sequence that hybridizes under stringent conditions to a second nucleic acid sequence, wherein the second sequence is a member of the group consisting of SEQ ID NO 1, SEQ ID NO 4, SEQ ID NO 7, SEQ ID NO 10, SEQ ID NO 13, SEQ ID NO 16, SEQ ID NO 19, SEQ ID NO 22, SEQ ID NO 25, SEQ ID NO 28, SEQ ID NO 31, SEQ ID NO 34;
or wherein the second sequence is a member of the group consisting of complements of SEQ ID NO 1, SEQ ID NO 4, SEQ ID NO 7, SEQ ID NO 10, SEQ ID NO 13, SEQ ID NO 16, SEQ ID NO 19, SEQ ID NO 22, SEQ ID NO 25, SEQ ID NO 28, SEQ ID NO 31, SEQ ID NO 34, SEQ ID NO 37, SEQ ID NO 40, and SEQ ID NO 43.
-
71. A screening method, the method comprising:
-
providing a polypeptide having an amino acid sequence that is at least 90% identical to a member of the group consisting of SEQ ID NO 9, SEQ ID NO 27, and SEQ ID NO 36;
exposing the polypeptide to a factor; and
determining that the factor has a specific binding affinity for the polypeptide. - View Dependent Claims (72, 73, 74, 75, 76, 77, 78)
-
- 79. A composition, the composition comprising a combination of a pharmaceutically acceptable carrier, VEGF, and at least one member of the group consisting of TDE1 and PTV.
- 81. A method of using a composition, the method comprising administering the composition to an animal, the composition comprising a polypeptide having an amino acid sequence that is at least 90% identical to SEQ ID NO 27.
Specification